• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Butterfly Network Reports Third Quarter 2024 Financial Results

    11/1/24 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email

    Delivered Quarterly Revenue of $20.6mm, 33% YoY Growth

    Raises Full Year Revenue and Adjusted EBITDA Guidance

    • Delivered quarterly Revenue of $20.6 million in Q3, representing 33% YoY growth
    • Reduced Q3 Net Loss by 38% and Net Cash Used in Operations by 50%
    • Launched iQ3 in Europe and opened new markets in Indonesia, the Netherlands, and Belgium
    • Announced the formation of Octiv™, a wholly owned subsidiary focused on bringing Butterfly's chip to new sectors

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

    Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "The Butterfly team is proud to report a fifth consecutive quarter in which we met or exceeded expectations. Our third quarter delivered growth of 33% versus 2023, while reducing cash use to a historic low. This success came from consistent, repeatable execution across all channels, driven by great products and a dedicated team. We've caught our stride and continue to gain momentum; with this, we are pleased to be giving improved guidance today on the top and bottom line.

    DeVivo continued, "What's more, while delivering strong results today, the Butterfly team has also kept our eye on the future. We remain fully committed to the strategic growth pillars we introduced at our March 2024 Investor Day. We look forward to sharing details of our operational and strategic highlights during today's conference call, including announcing new developments in our Butterfly HomeCare services business, and an exciting opportunity to fully capitalize on our Powered by Butterfly™ chip licensing program."

    Recent Operational and Strategic Highlights:

    • Butterfly's Return-on-Investment Validation: Published a case study demonstrating that University of Rochester Medical Center's system-wide deployment of Butterfly is enhancing patient care and financial performance. Additional research by Dr. Stephen Erickson at Jefferson Healthcare shows Butterfly devices pay for themselves quickly for individual practitioners, as well.
    • Medical Education Progress: Announced Kansas City University as the first U.S. medical school to leverage Butterfly ScanLab™ as the foundation of its POCUS curriculum.
    • International Market Expansion: Launched Butterfly iQ3 in Europe, and opened new markets in Indonesia, the Netherlands, and Belgium.
    • Butterfly Veterinary Advancements: Announced data from Kansas State University with Beef Cattle Institute on chute-side management of bovine respiratory disease, confirming the value of Butterfly in creating a new decision-making process for cattle operations globally.
    • Butterfly Garden Growth: Signed two new Butterfly Garden partners, bringing the portfolio to 17 companies. On October 28, 2024, HeartFocus by Deski announced the commercial launch of its AI-powered cardiac training app.
    • Butterfly HomeCare Pilot Announcement: In the fourth quarter 2024, Butterfly HomeCare is set to begin a pilot for virtual chronic care management with a leading Medicare Advantage provider to improve heart failure outcomes through AI-powered imaging.
    • Octiv™ Subsidiary Formation Announcement: as a next step to monetize the full value of Powered by Butterfly™, the Company plans to form Octiv – a wholly-owned subsidiary dedicated to bringing Butterfly's proprietary chip to new sectors. With the creation of Octiv, the Company's goal is to increase access to capital from new investors, while unlocking value for current Butterfly shareholders.
    • European Union's Restriction of Hazardous Substances (RoHS) Update: Butterfly leadership met with the officials responsible for the RoHS exemptions revision on September 11, 2024 in Brussels. During the discussion, Butterfly's revocation was welcomed with significant support from the European Commission representatives. Subsequently, on October 23, 2024, Butterfly re-submitted its revocation request, providing additional information and details suggested by the European Commission.

    Three Months Ended September 30, 2024 Financial Results

    Revenue: Total revenue was $20.6 million, up 33% from $15.4 million in the third quarter of 2023. U.S. revenue was $13.1 million, up 27% from prior year, driven by the recently launched next-generation iQ3 probe's higher selling price and increased enterprise software revenue. International revenue increased 36% year-over-year to $5.2 million, with new geographies contributing revenue. Other revenue contributed $2.3 million.

    • Product revenue was $13.5 million, an increase of 55% versus the prior year period, driven by the 37% increase in units fulfilled year-over-year and the iQ3's higher selling price.
    • Software and other services revenue was up 5% year-over-year at $7.0 million. Software and other services mix was 34% of revenue and decreased by 9 percentage points versus the prior year due to the higher product revenue achieved this quarter. Enterprise as a percentage of software revenue increased 5 percentage points year-over-year.

    Gross profit: Gross profit was $12.2 million versus $9.4 million in the prior year period, and adjusted gross profit was $12.3 million versus $9.4 million in the prior period. Gross margin decreased to 59.5% from 60.8% in the prior year period, and adjusted gross margin decreased to 60.0% from 60.8% in the prior year period. These decreases are primarily due to the higher cost to manufacture iQ3 including efficiencies in starting a new line and warranty expense; product mix, reflecting a higher proportion of product revenues; and higher amortization which reduced margin by approximately 90 basis points, largely offset by higher average selling prices.

    Operating expenses: Operating expenses were $29.5 million, down 30% from $41.9 million in the prior year period, due to previously announced reductions in force, as well as non-payroll spending rationalization across all areas.

    Total operating expenses excluding stock-based compensation and Other expense were $23.4 million, compared to $25.9 million in the third quarter of 2023, representing a decrease of 10%.

    Net loss: Net loss was $16.9 million, compared to $27.4 million in the prior year period.

    Adjusted EBITDA: Adjusted EBITDA loss was $8.4 million, compared to $12.5 million in the prior year period.

    Adjusted EPS: Adjusted EPS was ($0.05), compared to ($0.07) in the prior year period.

    Cash, cash equivalents, and restricted cash: Cash, cash equivalents, and restricted cash were $97.8 million as of September 30, 2024.

    Guidance

    Increased Revenue Guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2024 to:

    • Revenue guidance of $79 million to $81 million or over 20% growth
    • Improved adjusted EBITDA guidance by $5 million to a loss of $42 million - $40 million

    Reconciliation of GAAP to Adjusted

    Reconciliations of gross margin to adjusted gross margin and of net loss to adjusted EBITDA and adjusted EPS for the three and nine months ended September 30, 2024, and 2023 is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading "Non-GAAP Financial Measures."

    Conference Call

    A conference call and webcast to discuss third quarter 2024 financial performance and operational progress is scheduled for 8:00 am ET on November 1, 2024. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

    US domestic callers: +1 (833) 470-1428

    Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=71022

    Access Code: 668983

    After the live webcast, the call will be archived on Butterfly's Investor Relations page. In addition, a telephone replay of the call will be available until November 15, 2024, by dialing:

    U.S. (Toll-Free): +1 866-813-9403

    U.S. / International (Tolled): +1 929-458-6194

    Access Code: 736364

    About Butterfly Network

    Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore's Law, to launch its second-generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME's Best Inventions, Fast Company's World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

    Non-GAAP Financial Measures

    In addition to providing financial measures based on generally accepted accounting principles in the United States of America ("GAAP"), we provide additional financial measures that are not prepared in accordance with GAAP ("non-GAAP"). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.

    The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor's understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

    The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company's performance, you should consider adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.

    The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted gross profit to gross profit, adjusted gross margin to gross margin, and adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, future performance, commercialization and plans to deploy our products and services, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of products and services that we are currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to raise financing in the future; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.

    BUTTERFLY NETWORK, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except share and per share amounts)

    (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended September 30,

     

    Nine months ended September 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Product

     

    $

    13,538

     

     

    $

    8,753

     

     

    $

    39,478

     

     

    $

    29,874

     

    Software and other services

     

     

    7,023

     

     

     

    6,668

     

     

     

    20,227

     

     

     

    19,510

     

    Total revenue

     

     

    20,561

     

     

     

    15,421

     

     

     

    59,705

     

     

     

    49,384

     

    Cost of revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Product

     

     

    6,065

     

     

     

    3,929

     

     

     

    17,739

     

     

     

    13,765

     

    Software and other services

     

     

    2,263

     

     

     

    2,110

     

     

     

    6,870

     

     

     

    6,226

     

    Total cost of revenue

     

     

    8,328

     

     

     

    6,039

     

     

     

    24,609

     

     

     

    19,991

     

    Gross profit

     

     

    12,233

     

     

     

    9,382

     

     

     

    35,096

     

     

     

    29,393

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    8,844

     

     

     

    12,130

     

     

     

    28,975

     

     

     

    44,409

     

    Sales and marketing

     

     

    9,607

     

     

     

    9,012

     

     

     

    29,713

     

     

     

    28,776

     

    General and administrative

     

     

    9,353

     

     

     

    11,560

     

     

     

    29,868

     

     

     

    37,239

     

    Other

     

     

    1,675

     

     

     

    9,243

     

     

     

    3,639

     

     

     

    17,848

     

    Total operating expenses

     

     

    29,479

     

     

     

    41,945

     

     

     

    92,195

     

     

     

    128,272

     

    Loss from operations

     

     

    (17,246

    )

     

     

    (32,563

    )

     

     

    (57,099

    )

     

     

    (98,879

    )

    Interest income

     

     

    1,221

     

     

     

    1,903

     

     

     

    4,023

     

     

     

    5,714

     

    Interest expense

     

     

    (319

    )

     

     

    —

     

     

     

    (928

    )

     

     

    —

     

    Change in fair value of warrant liabilities

     

     

    (1,239

    )

     

     

    3,511

     

     

     

    (826

    )

     

     

    3,924

     

    Other income (expense), net

     

     

    717

     

     

     

    (217

    )

     

     

    517

     

     

     

    (256

    )

    Loss before provision for income taxes

     

     

    (16,866

    )

     

     

    (27,366

    )

     

     

    (54,313

    )

     

     

    (89,497

    )

    Provision for income taxes

     

     

    58

     

     

     

    2

     

     

     

    78

     

     

     

    82

     

    Net loss and comprehensive loss

     

    $

    (16,924

    )

     

    $

    (27,368

    )

     

    $

    (54,391

    )

     

    $

    (89,579

    )

    Net loss per common share attributable to Class A and B common stockholders, basic and diluted

     

    $

    (0.08

    )

     

    $

    (0.13

    )

     

    $

    (0.26

    )

     

    $

    (0.44

    )

    Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted

     

     

    212,774,085

     

     

     

    206,740,234

     

     

     

    211,109,792

     

     

     

    204,749,108

     

    BUTTERFLY NETWORK, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except share and per share amounts)

    (Unaudited)

     

     

     

     

     

     

     

     

    September 30,

     

    December 31,

     

     

    2024

     

    2023

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    93,758

     

     

    $

    134,437

     

    Accounts receivable, net

     

     

    20,621

     

     

     

    13,418

     

    Inventories

     

     

    73,271

     

     

     

    73,022

     

    Current portion of vendor advances

     

     

    4,351

     

     

     

    2,815

     

    Prepaid expenses and other current assets

     

     

    7,492

     

     

     

    7,571

     

    Total current assets

     

     

    199,493

     

     

     

    231,263

     

    Property and equipment, net

     

     

    21,176

     

     

     

    25,321

     

    Intangible assets, net

     

     

    9,266

     

     

     

    10,317

     

    Non-current portion of vendor advances

     

     

    15,082

     

     

     

    15,276

     

    Operating lease assets

     

     

    14,606

     

     

     

    15,675

     

    Other non-current assets

     

     

    5,649

     

     

     

    6,422

     

    Total assets

     

    $

    265,272

     

     

    $

    304,274

     

    Liabilities and stockholders' equity

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    3,651

     

     

    $

    5,090

     

    Deferred revenue, current

     

     

    16,425

     

     

     

    15,625

     

    Accrued purchase commitments, current

     

     

    131

     

     

     

    131

     

    Accrued expenses and other current liabilities

     

     

    22,585

     

     

     

    23,425

     

    Total current liabilities

     

     

    42,792

     

     

     

    44,271

     

    Deferred revenue, non-current

     

     

    7,035

     

     

     

    7,394

     

    Warrant liabilities

     

     

    1,652

     

     

     

    826

     

    Operating lease liabilities

     

     

    21,030

     

     

     

    22,835

     

    Other non-current liabilities

     

     

    10,931

     

     

     

    8,895

     

    Total liabilities

     

     

    83,440

     

     

     

    84,221

     

    Commitments and contingencies

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

    Class A common stock $.0001 par value; 600,000,000 shares authorized at September 30, 2024 and December 31, 2023; 186,557,521 and 181,221,794 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

     

     

    19

     

     

     

    18

     

    Class B common stock $.0001 par value; 27,000,000 shares authorized at September 30, 2024 and December 31, 2023; 26,426,937 shares issued and outstanding at September 30, 2024 and December 31, 2023

     

     

    3

     

     

     

    3

     

    Additional paid-in capital

     

     

    965,839

     

     

     

    949,670

     

    Accumulated deficit

     

     

    (784,029

    )

     

     

    (729,638

    )

    Total stockholders' equity

     

     

    181,832

     

     

     

    220,053

     

    Total liabilities and stockholders' equity

     

    $

    265,272

     

     

    $

    304,274

     

    BUTTERFLY NETWORK, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)

    (Unaudited)

     

     

     

     

     

     

     

     

     

    Nine months ended September 30,

     

     

    2024

     

    2023

    Cash flows from operating activities:

     

     

     

     

     

     

    Net loss

     

    $

    (54,391

    )

     

    $

    (89,579

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

     

     

    Depreciation, amortization, and impairments

     

     

    7,835

     

     

     

    8,332

     

    Non-cash interest expense

     

     

    926

     

     

     

    —

     

    Write-down of inventories

     

     

    15

     

     

     

    —

     

    Stock-based compensation expense

     

     

    15,794

     

     

     

    20,924

     

    Change in fair value of warrant liabilities

     

     

    826

     

     

     

    (3,924

    )

    Gain on lease termination

     

     

    —

     

     

     

    (214

    )

    Other

     

     

    945

     

     

     

    (478

    )

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable

     

     

    (8,158

    )

     

     

    711

     

    Inventories

     

     

    (264

    )

     

     

    (34,046

    )

    Prepaid expenses and other assets

     

     

    681

     

     

     

    2,354

     

    Vendor advances

     

     

    (1,342

    )

     

     

    15,646

     

    Accounts payable

     

     

    (1,440

    )

     

     

    1,092

     

    Deferred revenue

     

     

    441

     

     

     

    (423

    )

    Accrued purchase commitments

     

     

    —

     

     

     

    (1,934

    )

    Change in operating lease assets and liabilities

     

     

    (549

    )

     

     

    (671

    )

    Accrued expenses and other liabilities

     

     

    94

     

     

     

    (3,509

    )

    Net cash used in operating activities

     

     

    (38,587

    )

     

     

    (85,719

    )

     

     

     

     

     

     

     

    Cash flows from investing activities:

     

     

     

     

     

     

    Purchases of marketable securities

     

     

    —

     

     

     

    (297

    )

    Sales of marketable securities

     

     

    —

     

     

     

    76,484

     

    Purchases of property, equipment, and intangible assets, including capitalized software

     

     

    (2,286

    )

     

     

    (3,271

    )

    Sales of property and equipment

     

     

    36

     

     

     

    10

     

    Net cash (used in) provided by investing activities

     

     

    (2,250

    )

     

     

    72,926

     

     

     

     

     

     

     

     

    Cash flows from financing activities:

     

     

     

     

     

     

    Proceeds from exercise of stock options and warrants

     

     

    —

     

     

     

    228

     

    Net cash provided by financing activities

     

     

    —

     

     

     

    228

     

    Net decrease in cash, cash equivalents, and restricted cash

     

     

    (40,837

    )

     

     

    (12,565

    )

    Cash, cash equivalents, and restricted cash, beginning of period

     

     

    138,650

     

     

     

    166,828

     

    Cash, cash equivalents, and restricted cash, end of period

     

    $

    97,813

     

     

    $

    154,263

     

    BUTTERFLY NETWORK, INC.

    ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN

    (In thousands)

    (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended September 30,

     

     

    Nine months ended September 30,

     

     

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

    Revenue

     

    $

    20,561

     

     

    $

    15,421

     

     

    $

    59,705

     

     

    $

    49,384

     

    Cost of revenue

     

     

    8,328

     

     

     

    6,039

     

     

     

    24,609

     

     

     

    19,991

     

    Gross profit

     

    $

    12,233

     

     

    $

    9,382

     

     

    $

    35,096

     

     

    $

    29,393

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin

     

     

    59.5

    %

     

     

    60.8

    %

     

     

    58.8

    %

     

     

    59.5

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Add:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Write-downs and write-offs of inventories

     

     

    97

     

     

     

    —

     

     

     

    97

     

     

     

    —

     

    Adjusted gross profit

     

    $

    12,330

     

     

    $

    9,382

     

     

    $

    35,193

     

     

    $

    29,393

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted gross margin

     

     

    60.0

    %

     

     

    60.8

    %

     

     

    58.9

    %

     

     

    59.5

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

    $

    1,632

     

     

    $

    1,448

     

     

    $

    4,862

     

     

    $

    4,127

     

    % of revenue

     

     

    7.9

    %

     

     

    9.4

    %

     

     

    8.1

    %

     

     

    8.4

    %

    BUTTERFLY NETWORK, INC.

    ADJUSTED EBITDA AND ADJUSTED EPS

    (In thousands, except share and per share amounts)

    (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Included on the condensed consolidated statements of operations and comprehensive loss as:

     

    Three months ended September 30,

     

    Nine months ended September 30,

     

     

     

    2024

     

    2023

     

    2024

     

    2023

    Net loss

    Net loss

     

    $

    (16,924

    )

     

    $

    (27,368

    )

     

    $

    (54,391

    )

     

    $

    (89,579

    )

    Stock-based compensation

    R&D, S&M, and G&A

     

     

    4,411

     

     

     

    6,815

     

     

     

    15,794

     

     

     

    20,924

     

    Write-downs and write-offs of inventories

    Cost of revenue

     

     

    97

     

     

     

    —

     

     

     

    97

     

     

     

    —

     

    Change in fair value of warrant liabilities

    Change in fair value of warrant liabilities

     

     

    1,239

     

     

     

    (3,511

    )

     

     

    826

     

     

     

    (3,924

    )

    Other

    Other

     

     

    1,675

     

     

     

    9,243

     

     

     

    3,639

     

     

     

    17,848

     

    Other expense (income), net

    Other income (expense), net

     

     

    (717

    )

     

     

    217

     

     

     

    (517

    )

     

     

    256

     

    Adjusted net loss

     

     

     

    (10,219

    )

     

     

    (14,604

    )

     

     

    (34,552

    )

     

     

    (54,475

    )

    Interest income

    Interest income

     

     

    (1,221

    )

     

     

    (1,903

    )

     

     

    (4,023

    )

     

     

    (5,714

    )

    Interest expense

    Interest expense

     

     

    319

     

     

     

    —

     

     

     

    928

     

     

     

    —

     

    Provision for income taxes

    Provision for income taxes

     

     

    58

     

     

     

    2

     

     

     

    78

     

     

     

    82

     

    Depreciation and amortization

    Cost of revenue, R&D, S&M, and G&A

     

     

    2,618

     

     

     

    4,027

     

     

     

    7,835

     

     

     

    8,332

     

    Adjusted EBITDA

     

     

    $

    (8,445

    )

     

    $

    (12,478

    )

     

    $

    (29,734

    )

     

    $

    (51,775

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EPS

     

     

    $

    (0.05

    )

     

    $

    (0.07

    )

     

    $

    (0.16

    )

     

    $

    (0.27

    )

    Weighted average shares used to compute adjusted EPS

     

     

     

    212,774,085

     

     

     

    206,740,234

     

     

     

    211,109,792

     

     

     

    204,749,108

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241101201836/en/

    Get the next $BFLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    Financials

    Live finance-specific insights

    See more
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast before the market opens on February 28 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly

      2/18/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Reports Third Quarter 2024 Financial Results

      Delivered Quarterly Revenue of $20.6mm, 33% YoY Growth Raises Full Year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $20.6 million in Q3, representing 33% YoY growth Reduced Q3 Net Loss by 38% and Net Cash Used in Operations by 50% Launched iQ3 in Europe and opened new markets in Indonesia, the Netherlands, and Belgium Announced the formation of Octiv™, a wholly owned subsidiary focused on bringing Butterfly's chip to new sectors Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for th

      11/1/24 6:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Butterfly Network Reports First Quarter 2025 Financial Results

      Delivered on Quarterly Revenue and EBITDA Guidance Reiterate full year Revenue and Adjusted EBITDA guidance Quarterly Revenue of $21.2 million in Q1, representing 20% YoY growth Reduced Q1 Net Loss by 36% and Net Cash Used in Operations by 43% Raised $81.7 million of net proceeds through a public offering closed on January 31, 2025 Initiated clinical phase of Butterfly HomeCare congestive heart failure pilot program Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the first quarter ended March 31, 202

      5/2/25 6:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Participate at Oppenheimer 35th Annual Healthcare MedTech & Services Virtual Conference on March 18, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly") a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the Virtual Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 18, 2025. Joseph DeVivo, President, Chief Executive Officer & Chairman and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one investor meetings and take part in a Fireside Chat at 11:20am EDT. A webcast of the Fireside Chat will be available in the Events & Presentations section of the Butterfly investor website. To schedule a one-on-one meeting with Mr. DeVivo

      3/5/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BFLY
    SEC Filings

    See more

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • William Blair initiated coverage on Butterfly Network

      William Blair initiated coverage of Butterfly Network with a rating of Outperform

      3/17/25 7:23:53 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Lake Street initiated coverage on Butterfly Network with a new price target

      Lake Street initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

      9/10/24 8:07:39 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • UBS initiated coverage on Butterfly Network with a new price target

      UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $2.25

      3/29/23 7:12:28 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      9/3/24 7:10:06 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      8/30/24 4:05:41 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

      SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

      7/8/24 4:32:42 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • SEC Form 144 filed by Butterfly Network Inc.

      144 - Butterfly Network, Inc. (0001804176) (Subject)

      5/5/25 3:27:27 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Butterfly Network Inc.

      10-Q - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:28:43 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:25:19 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Director Robbins Larry bought $262,251 worth of shares (244,774 units at $1.07) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      9/4/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Director Robbins Larry bought $1,683,373 worth of shares (1,676,869 units at $1.00) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/30/24 4:18:35 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph bought $98,519 worth of shares (104,000 units at $0.95), increasing direct ownership by 2% to 7,009,221 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/7/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • EVP, CFO & COO Getz Heather C sold $144,069 worth of shares (65,456 units at $2.20), decreasing direct ownership by 2% to 2,919,274 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      5/7/25 4:18:53 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph sold $780,684 worth of shares (320,215 units at $2.44), decreasing direct ownership by 4% to 7,249,789 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/29/25 5:40:11 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Chief Technology Officer Stoica Andrei G sold $3,908 worth of shares (1,805 units at $2.17), decreasing direct ownership by 0.11% to 1,600,182 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/3/25 5:24:38 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    See more
    • Butterfly Network Appoints Steve Cashman as Chief Business Officer

      Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f

      9/3/24 8:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Avive Welcomes Katerina Miras as Vice President of Marketing

      SAN FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Katerina Miras as their Vice President of Marketing. A visionary marketing leader with extensive experience in medtech, Miras brings a wealth of expertise in creating memorable healthcare brands that accelerate commercial growth. "I am honored to join Avive's leadership team at such a transformative time for

      8/20/24 9:00:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties